Concepedia

John Frazer

JF

Statistics

Publications

10

Citations

290

H-Index

10

Active since

1972

Affiliations

Arena Pharmaceuticals (United States)(Current)

John Frazer is an author at Arena Pharmaceuticals (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1972–2018

10

Publications

10

Angiotensin (1–7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor

Ibragim Gaidarov, John W. Adams, John Frazer et al. · Cellular Signalling · 2018 · 56 citations

, , +9

Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration

David J. Unett, Joel Gatlin, Todd L. Anthony et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 54 citations

Isoaccepting transfer ribonucleic acids in liver and brain of young and old BC3F1 mice

John Frazer, Wen-Kuang Yang · Archives of Biochemistry and Biophysics · 1972 · 46 citations

, , +9

A new family of H3 receptor antagonists based on the natural product Conessine

Vincent J. Santora, Jonathan A. Covel, Rena Hayashi et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 31 citations · Full text

, , +10

APD791, 3-Methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology

John Adams, Juan Ignacio Ramirez, Yunqing Shi et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 24 citations

1–5 of 10